Later Generation TKIs as Frontline Therapy in CP CML

CE

Expert Insights for Hematology/Oncology Pharmacists on Later-Generation TKIs as Frontline Therapy in Chronic-Phase CML

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: May 13, 2025

Expiration: November 12, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Patient Case



  • RJ is a 67-yr-old patient referred to your hematology clinic for newly diagnosed chronic-phase CML, high risk by Sokal score

  • Past medical history is significant for poorly controlled type 2 diabetes

  • Current medications include metformin and insulin glargine 

Which of the following medications should be initiated for chronic-phase CML?

2.

Among the different approved BCR::ABL1 inhibitors, which of the following is a unique AE associated with asciminib?

3.

Patient Case



  • You are seeing a patient, TR, who has CP-CML

  • After 3 mo of TKI therapy with bosutinib, TR has had a significant reduction in their WBC count and improvement in splenomegaly

  • Their BCR::ABL1 comes back at 5% 

At this time, what is the most appropriate course of action with their CP-CML therapy?

4.

Which of the following was reported in the 96-wk update of results from the randomized phase III ASC4FIRST trial of oral asciminib vs investigator-selected TKI for patients with newly diagnosed Ph+ CP-CML after a median follow-up of approximately 2.2 yr in the overall patient population?